Cancer Heterogeneity and Plasticity

ISSN 2818-7792
Free Publication in 2025

[Cancer Heterogeneity and Plasticity @CHP_journal]

📢 Call for Papers — CHP Special Issue

Cancer evolves. Tumors adapt. Resistance emerges—and therapies fail.

📘 Molecular Understanding & Therapeutic Targeting of Cancer Heterogeneity and Plasticity

🧬 Heterogeneity
🔄 Plasticity
⚠️ Resistance & metastasis
💊 New strategies

💡 OA | No fees | No limits

📅 Apr 30, 2026 (priority deadline; submissions open thereafter)

🔗 https://t.co/5yRkcvclv2
🔗 More info: https://t.co/uX33cPup0J

#CancerResearch #TumorPlasticity

[Cancer Heterogeneity and Plasticity @CHP_journal]

📖 Commentary Spotlight — Rahul Kumar

Why does YAP1 targeting fail?

Rahul Kumar highlights:
🧠 Transcriptional plasticity drives resistance
🔗 TEAD–AP-1 cooperation sustains malignancy
💡 Supports co-targeting strategies
🔗 https://t.co/iRdXATHVvy
#CancerHeterogeneity #TherapyResistance

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 New Original Research in CHP

In gastric cancer peritoneal metastases (GCPMs),
Wu et al. (2026) reveal:

🧬 Targeting YAP1 alone triggers compensatory TAZ activation → sustaining oncogenic transcription

💡 Dual YAP1/TAZ targeting shows stronger antitumor effects

Great work by @shumei_song and team 👏

📄 https://t.co/LjbtJxNd6C
#GastricCancer #CancerPlasticity #HippoPathway

[Cancer Heterogeneity and Plasticity @CHP_journal]

🚀 Translational relevance:
Dual YAP1 + TAZ targeting:
✔️ ↓ Tumor growth (PDX)
✔️ ↓ Proliferation markers (KI67)
✔️ ↑ CD8+ T cell infiltration
✔️ ↓ M2 macrophages
💡 Enhanced response with anti-PD1

[Cancer Heterogeneity and Plasticity @CHP_journal]

🚀 Translational relevance:
Dual YAP1 + TAZ targeting:
✔️ ↓ Tumor growth (PDX)
✔️ ↓ Proliferation markers (KI67)
✔️ ↑ CD8+ T cell infiltration
✔️ ↓ M2 macrophages
💡 Enhanced response with anti-PD1

[Cancer Heterogeneity and Plasticity @CHP_journal]

YAP1 and TAZ are tightly linked in GC:
📈 Both are:
- Overexpressed in tumors vs normal
- Positively correlated across cohorts
- Co-localized in PDX models
🧩 Suggests coordinated oncogenic function

[Cancer Heterogeneity and Plasticity @CHP_journal]

Key insights from Rasouli et al., CHP 2026

🔹 HPV E6/E7 oncoproteins disable p53 and Rb, triggering genomic instability

🔹 HPV genome integration creates structural variants and oncogenic rewiring

🔹 Tumors display transcriptional and immune heterogeneity revealed by single-cell analyses

🔹 Combination therapies (immunotherapy, radiation, PARP inhibitors, vaccines) aim to overcome resistance
Figures illustrate HPV-driven carcinogenesis, integration patterns, oncogene activation, and combination treatment strategies.

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 New Review in CHP
Molecular heterogeneity of HPV-associated cancers and strategies to overcome treatment resistance

Rasouli et al. (2026) from @OhioState review how HPV-driven cancers evolve—from viral infection and genome integration to immune escape and therapy resistance.

Key concept:
HPV integration reshapes the host genome, tumor heterogeneity, and immune microenvironment, driving diverse treatment responses.

The review highlights emerging combination therapiestargeting viral oncogenes, host vulnerabilities, and tumor immunity.

🧬 Includes 4 figures + 1 clinical therapy table
🔗 https://t.co/eyr6ckYDnH

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 New Review Alert — first paper of CHP Volume 3 (2026)!
A comprehensive look at how breast cancers evade immunity across HR+, HER2+, and TNBC subtypes.
From antigen-presentation loss → checkpoint modulation → building an immunosuppressive TIME.
🧬 Includes 2 figures + 2 comprehensive tables
– Table 1: Subtype-specific TIME features
– Table 2: Clinical strategies targeting immune evasion

Key insight: BC subtypes use distinct TIME ecosystems but converge on shared immune-evasion circuits—shaping responses to immunotherapy.

Authors: Biswajit Das, Charles W. Winterbottom, & Shaheen S. Sikandar @ssikandar
UC Santa Cruz @ucsc
🔗 https://t.co/3uoK4CNuzn
(Figures 1 & 2 below)

[Cancer Heterogeneity and Plasticity @CHP_journal]

🙌 Special thanks to conference organizers @stephaniema912 @hku_med, @JustinLathia @ClevelandClinic, and @VivianLiLab @TheCrick for leading the Cellular Plasticity in Cancer @FASEBorg SRC — a truly global effort connecting scientists across disciplines and continents.

#CPCSRC #ScienceWithoutBorders #CancerResearch #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

🎉 Conference Highlights Published!

The inaugural FASEB Science Research Conference (SRC) on Cellular Plasticity in Cancer—held in Hong Kong (May 2025)—is now featured in CHP Journal!

Leading experts share how cancer cell plasticity drives heterogeneity, stemness & therapy resistance.
🔗 https://t.co/pQyr4N4ald

#CancerResearch #CHPJournal #CPCSRC #FASEB #TumorPlasticity

🧪 Featuring insights from:
Hans Clevers (@HansClevers @Roche) | Ankur Sharma (@garvaninstitute) | Stephanie Ma (@stephaniema912 @hkumed) | Vivian Li (@VivianLiLab @TheCrick) | Justin Lathia (@JustinLathia @ClevelandClinic) | Dean Tang (@DeanTang8 @RoswellPark)

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔍 Key Meeting Themes:

• Oncofetal reprogramming in the TME
• EMT-induced stemness & hybrid states
• Organoid & single-cell modeling
• Metabolic rewiring & immune evasion
• Novel therapies targeting stem-like states

Co-authored by 18 global leaders including Behrens, Golebiewska, Tam, Liu, Singh, Lee, Khaled & Miller.

This @FASEBorg SRC marks a milestone linking stemness, plasticity & translational oncology.
#CancerBiology #StemCells #Plasticity #FASEBSRC

[Cancer Heterogeneity and Plasticity @CHP_journal]

This review from Drs. Duhon and McLean dissects how tumor heterogeneity—spatial, temporal, and microenvironmental—impacts the efficacy and resistance of antibody-drug conjugates (ADCs).

Key insights:
🔹 7 FDA-approved ADCs now in solid tumors
🔹 Targeting strategies evolving from HER2 to Trop2, Nectin-4 & TF
🔹 Dual-target, dual-payload & immune-stimulating ADCs on the horizon
🔹 Combinatorial therapies (VEGF, ICI, hormonal) offer new hope
🧫 Figures & table below summarize the mechanisms, heterogeneity, and therapy design.

#Oncology #CancerTherapy #AntibodyDrugConjugates #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 Hot off the press in CHP!
“Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates”

by Ashley A. Duhon, MD, PhD (@ashleyaduhon) & Karen McLean, MD, PhD (@karenmcl13) from @RoswellPark.

ADCs are reshaping solid tumor therapy—but heterogeneity still challenges durable response.

🔗 https://t.co/lltSIdABNA

#CancerResearch #ADCs #TumorHeterogeneity #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

Continuing highlights from Li et al. (2025) —
Figures 5–6 show:
📦 Exosome-mediated CSC–TME signaling
🌫️ Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 Just published in CHP!

“Regulation of Cancer Stem Cells in the Tumor Microenvironment”

A comprehensive review by Aidan Li, Na Li, Yajing Yang, Linzhou Wang, Jessica Miao & Qi-En Wang (Ohio State Univ, Colleage of Medicine, Dpet of Radiation Oncology @OhioStateMed; OSU Comprehensive Cancer Center @OSUCCC_James)

🧬 CSCs reshape the tumor ecosystem → stemness, metastasis, drug resistance, immunosuppression.

OA Review 👉 https://t.co/y58any6mFO

#CancerResearch #TumorMicroenvironment #StemCells

[Cancer Heterogeneity and Plasticity @CHP_journal]

Key highlights from Li et al. (2025):
CSC–TME networking drives progression & therapy resistance.
🔹 CSCs recruit & polarize TAMs & MDSCs
🔹 CAFs & MSCs reinforce stemness & EMT
🔹 Exosomes deliver pro-tumoral cargo
🔹 Endothelial cells + hypoxia fuel plasticity
🔹 Exosome-mediated CSC–TME signaling
🔹 Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation

Figures 1–4: CSC crosstalk with TME 👇

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 New in CHP!
“Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response”
By Erik S. Knudsen, Thomas N. O’Connor & Agnieszka K. Witkiewicz @RoswellPark
Cancer cells bend cell-cycle rules—switching CDK/Cyclin drivers to thrive & resist therapy.
🔗 https://t.co/7VmrfP8spu

This review highlights:
- CDK4/6, CDK2, Cyclin D/E plasticity across tumors
- How RB, E2F & p16^INK4A rewire progression
- Why CDK inhibitors face rapid adaptive resistance
- Strategies to exploit vulnerabilities with combo therapy

#CancerBiology #CancerResearch #CellCycle #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

🩺 Clinical takeaways:

Table 1: Diagnostic tools for nonbone mPCa — PSMA PET, FDG PET, DLL3 imaging, tissue & liquid biopsies.

Table 2: Treatment strategies across mCSPC, mCRPC, NEPC, DNPC & novel therapies.

OA Review: https://t.co/Yp4MAon3TD

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 Fresh out of the oven in CHP!
Nonbone Metastasis in Prostate Cancer: Diagnosis & Treatment
New review by Genyu Du, Penghui Xu, Helen He Zhu & Na Jing(Ren Ji Hosp, Shanghai Cancer Inst, SJTU Med).

Focus: liver mets, tumor microenvironment, diagnostic strategies & novel therapies.

OA Review: https://t.co/qMYjbvB7vb
#ProstateCancer #Oncology